SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, Inc., a leading applied artificial intelligence company in healthcare, and NICO Corporation, a leader in modern minimally invasive interventional technologies for neurosurgery, have announced a collaboration to incorporate a new innovative clinical trial recruitment software from Viz.ai into the seminal ENRICH study which is investigating the treatment of intracerebral hemorrhages (ICHs).
The current standard of care for ICH calls for medical management of the patient, or a “watch and see” protocol, which allows blood that is pooled from the ruptured vessel to remain in the brain. The ENRICH trial is evaluating the efficacy and safety of early surgical evacuation (less than 24 hours) using a parafascicular (parallel to the brain’s fiber tracts) and transsulcal (through natural openings and folds of the brain) surgical approach. The goal of surgical evacuation is to maximize clot removal, achieve durable hemostasis, and achieve functional improvement of the patient.
Viz RECRUIT utilizes advanced artificial intelligence to automatically identify potential subjects for clinical trials. In ENRICH (Early MiNimally-invasive Removal of ICH), Viz RECRUIT will notify investigators immediately when a patient meets the eligibility criteria for enrollment. Study investigators can coordinate subject enrollment easily and securely through a dynamic, mobile, HIPAA-compliant platform.
“Automated detection and notification of suspected ICH patients using artificial intelligence has the potential to significantly speed ENRICH trial enrollment,” said Gustavo Pradilla MD, Assistant Professor of Neurosurgery at Emory University and Chief of Neurosurgery at Grady Memorial Hospital. “Viz's AI technology allows investigators to identify more trial eligible candidates and therefore potentially shorten clinical trials.”
“With the added value that Viz.ai is bringing to ENRICH with its award-winning imaging and workflow software, the trial can potentially be shortened through faster enrollment and provide a reduced time to randomization,” said Jim Pearson, President & CEO of NICO. “All this translates into being able to more quickly offer patients validated clinical trial outcomes as we work toward new ICH treatment protocols for this most deadly and debilitating form of stroke.”
ENRICH is a multi-center trial sponsored by NICO and led by the Emory Stroke Center of Emory University hospitals and the Marcus Stroke & Neuroscience Center of Grady Memorial Hospital, both in Atlanta. Ideal trial subjects are spontaneous supratentorial intracerebral hemorrhage patients with a potential chance of benefiting from surgical treatment based on well-defined criteria for study enrollment.
